Clinical Trials Browser

Phase 2 × Interventional × GRN163L peptide × Clear all

NCT05583552 2025-03-14

IMpress

Phase 2 Active not recruiting

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT01731951 2021-09-21

Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis

Phase 2 Completed

80 enrolled 31 charts

Myelodysplastic Syndromes, Myeloproliferative Disorders, Primary Myelofibrosis

NCT02011126 2018-08-07

Imetelstat Sodium in Treating Younger Patients With Relapsed or Refractory Solid Tumors

Phase 2 Withdrawn

CNSGastrointestinalSarcoma

Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral

NCT01836549 2018-07-20

Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors

Phase 2 Terminated

43 enrolled 14 charts

Astrocytoma, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma, Brain Stem Neoplasms

NCT01256762 2016-01-26

Imetelstat in Combination With Paclitaxel (With or Without Bevacizumab) in Patients With Locally Recurrent or Metastatic Breast Cancer

Phase 2 Completed

Breast Neoplasms